SALIX PHARMACEUTICALS, LTD.

Inactive Instrument

Salix Pharmaceuticals, Ltd. Stock

Equities

US7954351067

Pharmaceuticals

Chart Salix Pharmaceuticals, Ltd.

Duration

Period

Style

Latest news about Salix Pharmaceuticals, Ltd.

Endo : Valeant trumps Endo with $10.96 billion bid for Salix Pharma	15-03-16	RE
Bank of Montreal : TSX climbs on upbeat sentiment ahead of Fed meeting	15-03-16	RE
Wall St. bounces as dollar drops, Fed worries ease	15-03-16	RE
Endo : withdraws offer for Salix	15-03-16	RE
Valeant Pharmaceuticals Intl : TSX rebounds as energy shares advance with oil price	15-03-11	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	15-03-05	RE
AbbVie : Biotech buys get pharma M&A off to flying start in 2015	15-03-05	RE
AbbVie : boosts cancer drug pipeline with $21 billion Pharmacyclics deal	15-03-05	RE
Shire : buys Meritage Pharma for at least $70 million	15-02-24	RE
Canadian Natural Resources : TSX gains on Valeant news; financial stocks weigh	15-02-23	RE
Boeing : Nasdaq ends up 9th session; S&P 500, Dow dip with energy	15-02-23	RE
BioMarin Pharmaceutical : Exclusive - Rare disease drugmaker PTC Therapeutics explores sale: sources	15-02-23	RE
Salix Pharmaceuticals : Valeant nears deal to buy Salix for about $10 billion - WSJ	15-02-21	RE
Barrick Gold : TSX steady as bank shares offset Valeant gain	15-02-20	RE
Endo : Drugmaker Valeant close to buying Salix - source	15-02-20	RE

Press releases Salix Pharmaceuticals, Ltd.

Salix Pharmaceuticals : Confirms Receipt of an Unsolicited Proposal from Endo International plc	15-03-11	BU
Salix Pharmaceuticals : Reports 4Q2014 and FY2014 Results	15-03-02	BU
Salix Pharmaceuticals : Stockholders Encouraged to Contact Securities Law Firm about Takeover	15-02-27	PR
Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 1.5% Convertible Senior Notes Due 2019	15-02-25	BU
Salix Pharmaceuticals : Provides Notice of Anticipated Make-Whole Fundamental Change to Holders of Its 2.75% Convertible Senior Notes Due 2015	15-02-25	BU

More press releases

News in other languages on Salix Pharmaceuticals, Ltd.

Valeant Pharmaceuticals Intl : Le laboratoire canadien Valeant conclut l'acquisition de Salix	15-04-01
Le recul du dollar a favorisé le rebond de Wall Street	15-03-16
Allergan : Valeant relève son offre sur Salix, Endo jette l'éponge	15-03-16
BlackBerry : Les valeurs à suivre sur les marchés américains	15-03-16
Valeant Pharmaceuticals Intl : La nouvelle offre de Valeant sur Salix proche de $170 par action-source	15-03-13

Managers and Directors - Salix Pharmaceuticals, Ltd.

Managers	Title	Age	Since
Robert Spurr PSD	President	-	-
John Temperato SAM	Sales & Marketing	59	-

Company Profile

Sector

Pharmaceuticals

More about the company

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
KYOWA KIRIN CO. LTD.	+10.08%	9.12B
SK BIOPHARMACEUTICALS CO., LTD.	-15.94%	4.8B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+18.47%	3.72B
YUHAN CORPORATION	+1.89%	3.8B
INDIVIOR PLC	+25.23%	2.58B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-24.63%	2.36B
BETTA PHARMACEUTICALS CO., LTD.	-29.37%	2.11B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+2.55%	1.86B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals

The best tools reserved for subscribers to boost the performance of your investments!

Optimize my profits

fermer